본문 바로가기
KERD
논문KCI 등재

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Amit G. Singal|Karim Seif El Dahan|Darine Daher
대한간학회 (The korean Association for the Study of the Liver)|2023.02|Clinical and Molecular Hepatology|제29권 제1호|pp. 207-219

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

Hepatocellular carcinomaEarly detection of cancerNon-alcoholic fatty liver diseasePopulation surveillanceLiver neoplasm

초록

Non-alcoholic fatty liver disease (NAFLD) may progress to cirrhotic or non-cirrhotic hepatocellular carcinoma (HCC), and is currently recognized as the fastest growing cause of HCC worldwide. Accordingly, professional society guidelines recommend HCC surveillance in patients with cirrhosis from any etiology, and some may consider it beneficial in subgroups with non-cirrhotic NAFLD at higher risk for HCC. Notably, patients with NAFLD-related HCC are more likely to have HCC diagnosed at more advanced stages and have poorer outcomes when compared to other etiologies, and suboptimal effectiveness of HCC surveillance programs is a major culprit. In this review, we summarize the current guidelines for HCC surveillance and discuss its benefits versus potential harms for NAFLD patients. We also address the unique challenges of HCC surveillance in NAFLD, including higher proportion of NAFLD-related HCC without cirrhosis, poor recognition of at-risk patients, lack of consensus regarding the value of surveillance in non-cirrhotic NAFLD, subpar effectiveness of surveillance tools related to NAFLD phenotype, and preponderant surveillance underuse among NAFLD patients. Finally, we examine the effectiveness of currently used surveillance tools (i.e., ultrasound and alpha fetoprotein) and outline future perspectives including emerging risk stratification tools, imaging surveillance strategies (e.g., abbreviated magnetic resonance imaging protocols), blood-based biomarkers (e.g., GALAD and circulating tumor DNA panels), and interventions to improve surveillance adherence.

Abstract

Non-alcoholic fatty liver disease (NAFLD) may progress to cirrhotic or non-cirrhotic hepatocellular carcinoma (HCC), and is currently recognized as the fastest growing cause of HCC worldwide. Accordingly, professional society guidelines recommend HCC surveillance in patients with cirrhosis from any etiology, and some may consider it beneficial in subgroups with non-cirrhotic NAFLD at higher risk for HCC. Notably, patients with NAFLD-related HCC are more likely to have HCC diagnosed at more advanced stages and have poorer outcomes when compared to other etiologies, and suboptimal effectiveness of HCC surveillance programs is a major culprit. In this review, we summarize the current guidelines for HCC surveillance and discuss its benefits versus potential harms for NAFLD patients. We also address the unique challenges of HCC surveillance in NAFLD, including higher proportion of NAFLD-related HCC without cirrhosis, poor recognition of at-risk patients, lack of consensus regarding the value of surveillance in non-cirrhotic NAFLD, subpar effectiveness of surveillance tools related to NAFLD phenotype, and preponderant surveillance underuse among NAFLD patients. Finally, we examine the effectiveness of currently used surveillance tools (i.e., ultrasound and alpha fetoprotein) and outline future perspectives including emerging risk stratification tools, imaging surveillance strategies (e.g., abbreviated magnetic resonance imaging protocols), blood-based biomarkers (e.g., GALAD and circulating tumor DNA panels), and interventions to improve surveillance adherence.

참고문헌 (87)

  1. Adams LA, "The natural history of nonalcoholic fatty liver disease : a population-based cohort study", Gastroenterology, 129, pp.113~121 (2005)
  2. White DL, "Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review", Clin Gastroenterol Hepatol, 10, pp.1342~1359 (2012)
  3. Dyson J, "Hepatocellular cancer : the impact of obesity, type 2 diabetes and a multidisciplinary team", J Hepatol, 60, pp.110~117 (2014)
  4. Vernon G, "Systematic review : the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults", Aliment Pharmacol Ther, 34, pp.274~285 (2011)
  5. Younossi Z, "Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates", Clin Gastroenterol Hepatol, 17, pp.748~755 (2019)
  6. Huang DQ, "Changing global epidemiology of liver cancer from 2010 to 2019 : NASH is the fastest growing cause of liver cancer", Cell Metab, 34, pp.969~977 (2022)
  7. Piscaglia F, "Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease : a multicenter prospective study", Hepatology, 63, pp.827~838 (2016)
  8. Mittal S, "Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population", Clin Gastroenterol Hepatol, 13, pp.594~601 (2015)
  9. Geh D, "Hepatocellular carcinoma in nonalcoholic fatty liver disease-a review of an emerging challenge facing clinicians", Hepatobiliary Surg Nutr, 10, pp.59~75 (2021)
  10. Mittal S, "Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is sssociated with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 14, pp.124~131 (2016)
  11. Singal AG, "Rational HCC screening approaches for patients with NAFLD", J Hepatol, 76, pp.195~201 (2022)
  12. Sumida Y, "Surveillance of hepatocellular carcinoma in nonalcoholic fatty liver disease", Diagnostics(Basel), 10, pp.579~ (2020)
  13. Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
  14. European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
  15. Omata M, "AsiaPacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
  16. Zhang BH, "Randomized controlled trial of screening for hepatocellular carcinoma", J Cancer Res Clin Oncol, 130, pp.417~422 (2004)
  17. Singal AG, "HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis : a meta-analysis", J Hepatol, 77, pp.128~139 (2022)
  18. Aby E, "Inadequate hepatocellular carcinoma screening in patients with nonalcoholic steatohepatitis cirrhosis", J Clin Gastroenterol, 53, pp.142~146 (2019)
  19. Lo S, "Clinical features and survival of nonalcoholic fatty liver disease-related hepatocellular carcinoma", Hepatol Int, 10, pp.S437~ (2016)
  20. Harris RP, "The harms of screening : a proposed taxonomy and application to lung cancer screening", JAMA Intern Med, 174, pp.281~285 (2014)
  21. DeFrank JT, "The psychological harms of screening : the evidence we have versus the evidence we need", J Gen Intern Med, 30, pp.242~248 (2015)
  22. Singal AG, "Hepatocellular Carcinoma: Translational Precision Medicine Approaches", pp.27~51 (2019), Humana Press
  23. Rich NE, "Overdiagnosis of hepatocellular carcinoma : prevented by guidelines?", Hepatology, 75, pp.740~753 (2022)
  24. Rich NE, "Overdiagnosis : an understudied issue in hepatocellular carcinoma surveillance", Semin Liver Dis, 37, pp.296~304 (2017)
  25. Rich NE, "Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multicenter cohort of patients with cirrhosis", Hepatology, 72, pp.1654~1665 (2020)
  26. Nathani P, "Hepatocellular carcinoma tumour volume doubling time : a systematic review and meta-analysis", Gut, 70, pp.401~407 (2021)
  27. Hester CA, "Comparative analysis of nonalcoholic steatohepatitis-versus viral hepatitis-and alcohol-related liver disease-related hepatocellular carcinoma", J Natl Compr Canc Netw, 17, pp.322~329 (2019)
  28. Parikh ND, "Cost-effectiveness of hepatocellular carcinoma surveillance : an assessment of benefits and harms", Am J Gastroenterol, 115, pp.1642~1649 (2020)
  29. Andersson KL, "Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis", Clin Gastroenterol Hepatol, 6, pp.1418~1424 (2008)
  30. Ascha MS, "The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis", Hepatology, 51, pp.1972~1978 (2010)
  31. Sanyal AJ, "Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C", Hepatology, 43, pp.682~689 (2006)
  32. Kanwal F, "Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease", Gastroenterology, 155, pp.1828~1837 (2018)
  33. Alexander M, "Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD : real-world study of 18 million patients in four European cohorts", BMC Med, 17, pp.95~ (2019)
  34. Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American association for the study of liver diseases", Hepatology, 68, pp.723~750 (2018)
  35. Stefanini B, "Surveillance for hepatocellular carcinoma : current status and future perspectives for improvement", Expert Rev Anticancer Ther, 22, pp.371~381 (2022)
  36. Loomba R, "AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease : expert review", Gastroenterology, 158, pp.1822~1830 (2020)
  37. Pennisi G, "The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease : screening issue and future perspectives", Int J Mol Sci, 20, pp.5613~ (2019)
  38. Sanyal A, "Populationbased risk factors and resource utilization for HCC : US perspective", Curr Med Res Opin, 26, pp.2183~2191 (2010)
  39. Stine JG, "Systematic review with meta-analysis : risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases", Aliment Pharmacol Ther, 48, pp.696~703 (2018)
  40. Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)
  41. Orci LA, "Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease : a systematic review, meta-analysis, and meta-regression", Clin Gastroenterol Hepatol, 20, pp.283~292 (2022)
  42. Ioannou GN, "Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLDrelated cirrhosis for risk stratification", J Hepatol, 71, pp.523~533 (2019)
  43. Bianco C, "Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores", J Hepatol, 74, pp.775~782 (2021)
  44. Fujiwara N, "Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease", Sci Transl Med, 14, pp.eabo4474~ (2022)
  45. Fujiwara N, "A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis", Med(N Y), 2, pp.836~850 (2021)
  46. Goossens N, "Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis", Clin Transl Gastroenterol, 8, pp.e101~ (2017)
  47. Kanwal F, "Surveillance for hepatocellular carcinoma : current best practice and future direction", Gastroenterology, 157, pp.54~64 (2019)
  48. Bruix J, "Management of hepatocellular carcinoma : an update", Hepatology, 53, pp.1020~1022 (2011)
  49. Tzartzeva K, "Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis : a metaanalysis", Gastroenterology, 154, pp.1706~1718 (2018)
  50. Jamak Modaresi Esfeh, "Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard", Clinical and Molecular Hepatology, 26(1), pp.54~59 (2020), 대한간학회
  51. Simmons O, "Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis", Aliment Pharmacol Ther, 45, pp.169~177 (2017)
  52. Schoenberger H, "Dynamic changes in ultrasound quality for hepatocellular carcinoma screening in patients with cirrhosis", Clin Gastroenterol Hepatol, 20, pp.1561~1569 (2022)
  53. Samoylova ML, "Predictors of ultrasound failure to detect hepatocellular carcinoma", Liver Transpl, 24, pp.1171~1177 (2018)
  54. Singal AG, "International liver cancer association(ILCA)white paper on biomarker development for hepatocellular carcinoma", Gastroenterology, 160, pp.2572~2584 (2021)
  55. Gopal P, "Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis", Clin Gastroenterol Hepatol, 12, pp.870~877 (2014)
  56. Vipani A, "Decreasing trend of serum α-fetoprotein level in hepatocellular carcinoma", Clin Gastroenterol Hepatol, 20, pp.1177~1179 (2022)
  57. Lee E, "Improving screening for hepatocellular carcinoma by incorporating data on levels of α-fetoprotein, over time", Clin Gastroenterol Hepatol, 11, pp.437~440 (2013)
  58. Tayob N, "Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm", Clin Gastroenterol Hepatol, 14, pp.469~475 (2016)
  59. Kim HL, "Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis", Hepatology, 69, pp.1599~1613 (2019)
  60. Gupta P, "Abbreviated MRI for hepatocellular carcinoma screening : a systematic review and meta-analysis", J Hepatol, 75, pp.108~119 (2021)
  61. Park HJ, "Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high-risk patients", Liver Int, 42, pp.2080~2092 (2022)
  62. Yang JD, "GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score", Cancer Epidemiol Biomarkers Prev, 28, pp.531~538 (2019)
  63. Johnson PJ, "The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers", Cancer Epidemiol Biomarkers Prev, 23, pp.144~153 (2014)
  64. Berhane S, "Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients", Clin Gastroenterol Hepatol, 14, pp.875~886 (2016)
  65. Best J, "GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis", Clin Gastroenterol Hepatol, 18, pp.728~735 (2020)
  66. Singal AG, "GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis", Hepatology, 75, pp.541~549 (2022)
  67. Tran NH, "Using cell-free DNA for HCC surveillance and prognosis", JHEP Rep, 3, pp.100304~ (2021)
  68. Chalasani NP, "Validation of a novel multitarget blood test shows high sensitivity to detect early stage hepatocellular carcinoma", Clin Gastroenterol Hepatol, 20, pp.173~182 (2022)
  69. Singal AG, "Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance : results of a network meta-analysis", Hepatol Commun, 6, pp.2925~2936 (2022)
  70. Lin N, "A multi-analyte cellfree DNA-based blood test for early detection of hepatocellular carcinoma", Hepatol Commun, 6, pp.1753~1763 (2022)
  71. Moshiri F, "Circulating miR-106b-3p, miR-101-3p and miR1246 as diagnostic biomarkers of hepatocellular carcinoma", Oncotarget, 9, pp.15350~15364 (2018)
  72. Zhang L, "Identification of key hydroxymethylated genes and transcription factors associated with alpha-fetoprotein-negative hepatocellular carcinoma", DNA Cell Biol, 38, pp.1346~1356 (2019)
  73. Lewinska M, "The altered serum lipidome and its diagnostic potential for non-alcoholic fatty liver(NAFL)-associated hepatocellular carcinoma", EBioMedicine, 73, pp.103661~ (2021)
  74. Singal A, "Meta-analysis : surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis", Aliment Pharmacol Ther, 30, pp.37~47 (2009)
  75. Trinchet JC, "Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis : a randomized trial comparing 3-and 6-month periodicities", Hepatology, 54, pp.1987~1997 (2011)
  76. Singal AG, "Utilization of hepatocellular carcinoma surveillance among American patients : a systematic review", J Gen Intern Med, 27, pp.861~867 (2012)
  77. Singal AG, "Failure rates in the hepatocellular carcinoma surveillance process", Cancer Prev Res(Phila), 5, pp.1124~1130 (2012)
  78. Marquardt P, "Hepatocellular carcinoma screening process failures in patients with cirrhosis", Hepatol Commun, 5, pp.1481~1489 (2021)
  79. Parikh ND, "Barriers to surveillance for hepatocellular carcinoma in a multicenter cohort", JAMA Netw Open, 5, pp.e2223504~ (2022)
  80. Simmons OL, "Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance", Clin Gastroenterol Hepatol, 17, pp.766~773 (2019)
  81. Farvardin S, "Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis", Hepatology, 65, pp.875~884 (2017)
  82. Singal AG, "Patient-reported barriers are associated with receipt of hepatocellular carcinoma surveillance in a multicenter cohort of patients with cirrhosis", Clin Gastroenterol Hepatol, 19, pp.987~995 (2021)
  83. Singal AG, "Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis : a randomized clinical trial", Hepatology, 69, pp.121~130 (2019)
  84. Wolf E, "Use of hepatocellular carcinoma surveillance in patients with cirrhosis : a systematic review and meta-analysis", Hepatology, 73, pp.713~725 (2021)
  85. Singal AG, "Multicenter randomized clinical trial of a mailed outreach strategy for hepatocellular carcinoma surveillance", Clin Gastroenterol Hepatol (2021)[DOI]
  86. Singal AG, "Benefits and harms of hepatocellular carcinoma surveillance in a prospective cohort of patients with cirrhosis", Clin Gastroenterol Hepatol, 19, pp.1925~1932 (2021)
  87. Beste LA, "Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder", Clin Gastroenterol Hepatol, 13, pp.172~179 (2015)

관련 논문AI추천

Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?Amit G. Singal, Ibrahim A. Hanouneh, Naim Alkhouri대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제3호Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?Cheng Han Ng, Daniel Q. Huang, Darren Jun Hao Tan, Margaret LP Teng대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinomaBo Hyun Kim, Joong-Won Park, Yuri Cho대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatmentAmit G. Singal, Ghassan K. Abou-Alfa, Ju Dong Yang, Neehar D. Parikh, Neil Mehta, Pojsakorn Danpanichkul, Soo Young Hwang, Vatche Agopian대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Surveillance for hepatocellular carcinoma: It is time to move forwardBo Hyun Kim, Joong-Won Park, Yuri Cho대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제4호Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?심주현대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제2호

이 간행물의 다른 논문 (46건)

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detectionLuma Melo, David Martí-Aguado, Ramón Bataller, Concepción Gómez-Medinapp. 1-15PrefaceYoon Jun Kimpp. 2-2PrefaceSeung Up Kimpp. 3-3Non-alcoholic fatty liver disease: Definition and subtypesSeul Ki Han, 김문영, 백순구pp. 5-16Management of refractory ascitesFlorence Wongpp. 16-32
원문 보기